Legal & General Group Plc decreased its position in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 2.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,015 shares of the company’s stock after selling 206 shares during the period. Legal & General Group Plc’s holdings in Aerie Pharmaceuticals were worth $319,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in AERI. Guggenheim Capital LLC raised its stake in Aerie Pharmaceuticals by 4.2% in the fourth quarter. Guggenheim Capital LLC now owns 34,135 shares of the company’s stock worth $1,292,000 after buying an additional 1,384 shares during the last quarter. First Mercantile Trust Co. increased its position in Aerie Pharmaceuticals by 29.9% in the first quarter. First Mercantile Trust Co. now owns 7,031 shares of the company’s stock worth $319,000 after buying an additional 1,620 shares during the period. Quantbot Technologies LP bought a new position in Aerie Pharmaceuticals during the first quarter worth $107,000. Ameritas Investment Partners Inc. bought a new position in Aerie Pharmaceuticals during the first quarter worth $108,000. Finally, Teachers Advisors LLC increased its position in Aerie Pharmaceuticals by 5.1% in the first quarter. Teachers Advisors LLC now owns 49,726 shares of the company’s stock worth $2,255,000 after buying an additional 2,402 shares during the period. Institutional investors own 87.74% of the company’s stock.
Shares of Aerie Pharmaceuticals, Inc. (AERI) opened at 53.05 on Friday. The company’s market cap is $1.93 billion. Aerie Pharmaceuticals, Inc. has a 1-year low of $18.52 and a 1-year high of $59.50. The company has a 50 day moving average of $54.36 and a 200 day moving average of $48.37.
ILLEGAL ACTIVITY NOTICE: “Legal & General Group Plc Sells 206 Shares of Aerie Pharmaceuticals, Inc. (AERI)” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.com-unik.info/2017/08/19/aerie-pharmaceuticals-inc-aeri-position-lowered-by-legal-general-group-plc-updated.html.
A number of equities analysts have recently weighed in on AERI shares. Stifel Nicolaus reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, May 26th. Cowen and Company set a $100.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 26th. Aegis increased their target price on shares of Aerie Pharmaceuticals from $63.00 to $70.00 and gave the stock a “buy” rating in a research report on Thursday, May 25th. Cantor Fitzgerald set a $56.00 target price on shares of Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 24th. Finally, HC Wainwright reissued a “buy” rating and set a $69.00 target price on shares of Aerie Pharmaceuticals in a research report on Thursday, May 25th. One research analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Aerie Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $66.08.
In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $55.95, for a total value of $1,119,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 9.36% of the stock is owned by corporate insiders.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
What are top analysts saying about Aerie Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aerie Pharmaceuticals Inc. and related companies.